PNC Financial Services Group’s OptimizeRx OPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.6K Buy
2,031
+1,863
+1,109% +$10.7K ﹤0.01% 4025
2026
Q1
$1.05K Buy
168
+106
+171% +$984 ﹤0.01% 4749
2025
Q4
$760 Sell
62
-197
-76% -$3.22K ﹤0.01% 4753
2025
Q3
$5.31K Sell
259
-52
-17% -$825 ﹤0.01% 4179
2025
Q2
$4.2K Sell
311
-35
-10% -$383 ﹤0.01% 4204
2025
Q1
$3K Buy
+346
New +$2.12K ﹤0.01% 4231
2024
Q2
Sell
-54
Closed -$656 4876
2024
Q1
$656 Buy
+54
New +$783 ﹤0.01% 4450
2023
Q1
Sell
-1,192
Closed -$20K 4782
2022
Q4
$20K Sell
1,192
-163
-12% -$2.82K ﹤0.01% 3467
2022
Q3
$21K Sell
1,355
-259
-16% -$5.12K ﹤0.01% 3423
2022
Q2
$45K Buy
1,614
+919
+132% +$27.2K ﹤0.01% 3052
2022
Q1
$26K Sell
695
-54
-7% -$2.39K ﹤0.01% 3448
2021
Q4
$47K Buy
+749
New +$56.8K ﹤0.01% 3141
2020
Q1
Sell
-9,332
Closed -$96K 4012
2019
Q4
$96K Hold
9,332
﹤0.01% 2519
2019
Q3
$136K Buy
+9,332
New +$144K ﹤0.01% 2368

Other funds holding OPRX

PNC Financial Services Group's OPRX Position: Q2 2026 in Review

PNC Financial Services Group increased its OptimizeRx (OPRX) stake by 1,109% in Q2 2026, buying an estimated $10.7K and bringing the position to 2,031 shares worth $11.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4025.

PNC Financial Services Group first reported a position in OPRX in Q3 2019 and has held it in 14 quarters since. The position peaked at $136K in Q3 2019. 34 funds tracked by Wall St. Rank hold OPRX as of Q2 2026.

  • PNC Financial Services Group held 2,031 shares of OptimizeRx worth $11.6K as of Q2 2026.
  • PNC Financial Services Group bought 1,863 OptimizeRx shares in Q2 2026, an estimated $10.7K.
  • OptimizeRx made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4025 holding.
  • PNC Financial Services Group first reported a position in OptimizeRx in Q3 2019 and has held it in 14 quarters since.
  • PNC Financial Services Group's OptimizeRx position peaked at $136K in Q3 2019.
  • 34 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.